Skip to main content
ISTH 2023 Main banner
Back

    Poster Networking

    Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies

    Poster Networking Session

    PB1371 - Platelet activation with the Aeson Bioprosthetic Total Artificial Heart: insight from aspirin treatment and outcomes

    Tuesday, June 27, 2023
    18:30 – 19:30 ET
    Room: Exhibition

      Presenting Author(s)

    • David Smadja, PhD (he/him/his)

      Professor of hematology
      Université Paris Cité, Ile-de-France, France

      • Co-Author(s)

    • CP

      Christophe Peronino

      PhD student
      Carmat
      Paris, Ile-de-France, France

    • LJ

      Léa Jilet

      engineer
      carmat
      Velisy, Ile-de-France, France

    • PI

      Peter Ivak

      assistant professor
      IKEM
      Prague, Stredocesky kraj, Czech Republic

    • YP

      Yury Pia

      Professor
      Astana University
      astana, Astana, Kazakhstan

    • Aurelien Philippe

      PhD student
      UniVersité Paris Cité et Inserm 1140
      Paris, Ile-de-France, France

    • CL

      Christian Latremouille

      Professor
      Carmat
      Paris, Ile-de-France, France

    • Fg

      Finn gustafsson

      Professor
      Copenhague University
      Copenhague, Sjelland, Denmark

    • FR

      Faiz Ramjankhan

      Professor
      Utrecht University
      Utrecht, Utrecht, Netherlands

    • JR

      Jean-christian Roussel

      Professor
      CHU Nantes
      Nantes, Bretagne, France

    • AV

      André Vincentelli

      MD, PhD
      Cardiac Surgery, Lille Hospital University, 59000, Lille, France
      Lille, Nord-Pas-de-Calais, France

    • EF

      Erwan Flecher

      MD, PhD
      Department of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, University of Rennes 1, Signal and Image Treatment Laboratory (LTSI), Inserm U1099, Rennes, France.
      Rennes, Bretagne, France

    • PG

      Pascale Gaussem

      Professor
      Université Paris Cité, INSERM U1140, Innovative Therapies in Haemostasis, France
      Paris, Ile-de-France, France

    • PJ

      Piet Jansen

      Medical Director
      Carmat
      Velisy, Ile-de-France, France

    • IN

      Ivan Netuka

      Professor
      IKEM
      Prague, Stredocesky kraj, Czech Republic

    Background: The Aeson bioprosthetic total artificial heart (A-TAH) is a pulsatile and autoregulated device.

    Aims: The aim of this study was to evaluate the level of platelet activation secondary to A-TAH implantation.

    Methods: We examined the level of platelet activation markers in adult patients receiving A-TAH support (n=16) during clinical follow-up by quantifying sP-selectin (sP-sel) and sCD40L in plasma.

    Results: The cumulative duration of A-TAH support was 3587 days. Before implantation, sCD40L was 2684.6 pg/mL (954.0-16706.1) and remained steady after implantation [3305.8 pg/mL (1234.2-12327.5), 3300.5 pg/mL (1041.5-8370.1), and 2560.0 pg/mL (1325.5-14039.5), respectively, at < 3 months, 3–6 months and >6 months; non-significant difference along time-period]. sP-sel was 33997.0 pg/mL (16019.6-73377.6) and remained steady after implantation [33580.1 pg/mL (13979.8-53395.2), 33204.9 pg/mL (15332.6-67263.4), and 34684.5 pg/mL (14084.9-49206.0), respectively, at < 3 months, 3–6 months and >6 months; non-significant difference along time-period]. Levels sP-sel and sCD40L analysed according to aspirin or heparin use did not change. Finally, no relation existed between pericardial effusion and aspirin use according to timing of aspirin start and drain removal.

    Conclusion(s): We demonstrated that A-TAH does not induce significant platelet activation. Absence of relationship between aspirin and platelet activation levels or pericardial effusion may support potential for withdrawal of antiplatelet therapy after A-TAH implantation in the future.